Samir Rahbe, MD
Internal Medicine · Cleveland, TNNPI 1073665642
Payments from drug & device makers
Across 166 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$360
- Pfizer$339
- Otsuka America Pharmaceutical, Inc.$314
- Merck$219
- Johnson & Johnson$208
- Lilly USA, LLC$126
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,902100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $360 |
| Pfizer | 17 | $339 |
| Otsuka America Pharmaceutical, Inc. | 18 | $314 |
| Merck | 15 | $219 |
| Johnson & Johnson | 12 | $208 |
| Lilly USA, LLC | 8 | $126 |
| Lundbeck LLC | 5 | $119 |
| AbbVie(2 entities) | 6 | $103 |
| Sanofi-aventis U.S. LLC | 7 | $98 |
| Amarin Pharma, Inc. | 5 | $97 |
| Amgen | 5 | $84 |
| Exact Sciences | 4 | $83 |
| Novartis | 5 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Intra-sana Laboratories | 4 | $79 |
| Akcea Therapeutics, Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $51 |
| Bayer | 2 | $46 |
| Eisai Inc. | 3 | $44 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| GSK | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Medtronic | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Amicus Therapeutics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$2,902 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 390 | $168,995 |
| OzempicSemaglutide | 126 | $159,936 |
| XareltoRivaroxaban | 329 | $134,613 |
| MounjaroTirzepatide | 75 | $84,421 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $72,995 |
| TrulicityDulaglutide | 56 | $71,393 |
| RexultiBrexpiprazole | 58 | $54,319 |
| JardianceEmpagliflozin | 65 | $51,094 |
| XifaxanRifaximin | 29 | $45,552 |
| EntrestoSacubitril/Valsartan | 57 | $36,451 |
| FarxigaDapagliflozin Propanediol | 61 | $34,167 |
| JanuviaSitagliptin Phosphate | 34 | $33,102 |
| LinzessLinaclotide | 55 | $31,273 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $29,349 |
| Nurtec OdtRimegepant Sulfate | 24 | $26,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt, Premarin | $339 | $202,963438 claims |
| Novo NordiskOzempic, Rybelsus | $20 | $171,719139 claims |
| Lilly USA, LLCMounjaro, Trulicity | $126 | $155,814131 claims |
| Johnson & JohnsonXarelto | $208 | $134,613329 claims |
| GSKTrelegy Ellipta | $27 | $72,995107 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $314 | $54,31958 claims |
| Boehringer IngelheimJardiance | $31 | $51,09465 claims |
| AstraZenecaFarxiga, Brilinta | $360 | $46,444100 claims |
| MerckJanuvia, Verquvo | $219 | $46,12752 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $12 | $45,55229 claims |
| NovartisEntresto | $82 | $36,45157 claims |
| AbbVieLinzess | $103 | $31,27355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Cleveland
- Charles RudolphCleveland$22K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.